Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEGA THERAPEUTICS, INC.

(OMGA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
16.91(c) 16.49(c) 18.09(c) 16.99(c) 17.73(c) Last
35 295 93 768 101 554 62 361 61 274 Volume
-0.53% -2.48% +9.70% -6.08% +4.36% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -71,6 M - -
Net cash position 2021 209 M - -
P/E ratio 2021 -6,60x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -156 M - -
Net cash position 2022 79,5 M - -
P/E ratio 2022 -4,76x
Yield 2022 -
Capitalization 847 M 847 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees -
Free-Float 96,3%
More Financials
Company
Omega Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused in a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. It is developing OMEGA Epigenomic Programming platform is designed to coopt nature's universal operating system by harnessing the power of epigenetics, the mechanism for gene control... 
More about the company
All news about OMEGA THERAPEUTICS, INC.
11/18Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare C..
PR
11/10Omega Therapeutics Narrows Loss in Q3
MT
11/10Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corpor..
PU
11/10OMEGA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/10Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corpor..
PR
11/09Omega Therapeutics to Present at the Jefferies London Healthcare Conference
PR
11/08OMEGA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
10/14OMEGA THERAPEUTICS : Working With Stanford University to Explore Use of Omega Epigenomic C..
MT
10/14OMEGA THERAPEUTICS : Announces Strategic Research Collaboration with Stanford University S..
PR
10/14Omega Therapeutics, Inc. Announces Strategic Research Collaboration with Stanford Unive..
CI
09/27OMEGA THERAPEUTICS : to Present at the Chardan Virtual 5th Annual Genetic Medicines Confer..
PR
09/20OMEGA THERAPEUTICS, INC.(NASDAQGS : OMGA) added to S&P TMI Index
CI
09/10OMEGA THERAPEUTICS' : Q2 Loss Widens as Operating Expenses Rise
MT
09/10OMEGA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
09/10OMEGA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Outlines Key Corpor..
PR
More news
News in other languages on OMEGA THERAPEUTICS, INC.
11/10Omega Therapeutics réduit sa perte au troisième trimestre
09/10La perte d'Omega Therapeutics au deuxième trimestre se creuse en raison de l'augmentati..
07/30Omega Therapeutics chute lors de son entrée au Nasdaq après avoir fixé le prix de son i..
More news
Analyst Recommendations on OMEGA THERAPEUTICS, INC.
More recommendations
Chart OMEGA THERAPEUTICS, INC.
Duration : Period :
Omega Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEGA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 17,73 $
Average target price 29,50 $
Spread / Average Target 66,4%
EPS Revisions
Managers and Directors
Mahesh Karande President, Chief Executive Officer & Director
Roger A. Sawhney Chief Financial Officer
Noubar B. Afeyan Chairman
Thomas McCauley Chief Scientific Officer
Mary T. Szela Director
Sector and Competitors
1st jan.Capi. (M$)
OMEGA THERAPEUTICS, INC.0.00%812
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-40.67%24 625